GlassScriptPhysician profile
Jake Hutto
NPI 1154783843
$12,963.27
in general payments reported to CMS, 2019-2025
26 companies · $3,246 in 2025
The $3,246 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2021: $541 · 2022: $2,561 · 2023: $2,982 · 2024: $3,525 · 2025: $3,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,710 · Education: $42.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,709.99 |
| Education | $42.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,531.98 | 2021-2025 | Krystexxa, Enbrel, Otezla |
| Abbvie INC. | $2,117.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,082.94 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $863.51 | 2021-2025 | Acthar |
| Janssen Biotech, INC. | $808.69 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Glaxosmithkline, LLC. | $803.03 | 2021-2025 | Benlysta |
| Ucb, INC. | $736.58 | 2021-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $720.73 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $579.91 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $578.78 | 2022-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $564.55 | 2021-2025 | |
| Organon LLC | $315.45 | 2023-2025 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $308.59 | 2021-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $234.11 | 2022-2025 | |
| Genentech USA, INC. | $190.06 | 2019-2025 | Actemra, Gazyva, Rituxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $176.13 | 2024-2025 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.49 | 2023-2024 | Ofev |
| Genzyme Corporation | $52.56 | 2023 | |
| Octapharma USA, INC. | $49.72 | 2022-2024 | Octagam Immune Globulin (Human) |
| Hospira, INC. | $31.34 | 2024 | |
| Lilly USA, LLC | $27.26 | 2024 | Taltz |
| Kiniksa Pharmaceuticals, LTD. | $27.24 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $23.40 | 2025 | Strensiq |
| Scilex Pharmaceuticals INC. | $21.57 | 2024 | |
| Bioventus LLC | $15.39 | 2024 | Durolane |
| Sandoz INC. | $14.53 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Hutto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.